---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-279016"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:49:33.841596+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options

## Summary
- Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.
- Compensation: $500k base salary, 40% bonus target, inducement options for 100,000 shares vesting over 4 years.
- Ledell previously COO at AVEO Oncology, Enzyvant Therapeutics, Compass Therapeutics, and Horizon Discovery Group.
- Appointment supports KalVista's preparation for potential sebetralstat launch (HAE); PDUFA goal date June 17, 2025.

## SEC filing metadata
- accession: 0001193125-24-279016
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/0001193125-24-279016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524279016/d866245d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-279016
- JSON: https://secwatch.observer/filing/0001193125-24-279016.json
- Plain text: https://secwatch.observer/filing/0001193125-24-279016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.